Kayhan Erturk

Prof. Dr. Kayhan Erturk

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2017 in Cancer Investigation
Verified
Journal Article
Closed access
FTFaruk Tas
Faruk Tas
KEKayhan Erturk
Kayhan Erturk
Tumor infiltrating lymphocytes (TILs) invade and disrupt melanoma cells and their clinical roles remain controversial. In this study, we aimed to determine the clinical significance of the TILs status in cutaneous melanoma patients (CMPs). Of 750 CMPs enrolled into this study 486 (64.8%) had lesions with TILs. The patients with TILs more likely had nodular histology, presence of histological regression, and absence of regional lymph node involvement. However, its presence was not associated with outcome. In conclusion, presence of TILs may be only an independent predictor for absence of nodal involvement but it is not associated with recurrence and survival in CMPs.

22 August 2019 in Wiener klinische Wochenschrift
Verified
Journal Article
Closed access
PDF file
KEKayhan Erturk
Kayhan Erturk
SKSule Karaman
Sule Karaman
NDNergiz Dagoglu
Nergiz Dagoglu
MSMurat Serilmez
Murat Serilmez
DDDerya Duranyildiz
Derya Duranyildiz
FTFaruk Tas
Faruk Tas

1 March 2020 in Dermatologic Therapy
Verified
Journal Article
Closed access
PDF file
FTFaruk Tas
Faruk Tas
KEKayhan Erturk
Kayhan Erturk
The prognostic significance of BRAF mutations in the natural course of melanoma is controversial. The aim of study was to assess the prognostic significance of BRAF V600E mutation in cutaneous melanoma patients. A total of 151 melanomas were included in the study. BRAF V600E mutation was detected using the real-time PCR. BRAF V600E mutation rate was 51%. BRAF mutation rate was higher for young patients (61.4%) and upper limbs (63.2%), trunk (59.3%) and head and neck (59.2%) were the most frequently afflicted sites in BRAF-mutant patients, whereas lower limbs were mostly affected in BRAF-wild patients (77.8%). Likewise, acral melanomas rarely harbored BRAF mutation (17.1%). The disease-free survivals regarding the entire and Stage III cohorts were longer in the BRAF-mutant group than in the BRAF-wild group (p = .006 and p = .004, respectively), whereas Stage I-II patients had no survival differences between BRAF statuses (p = .2). Likewise, BRAF-mutant patients had better overall survival (OS) time compared to BRAF-wild patients in all stages (p = .01), in Stage III (p = .01), and in Stage IV patients (p = .001). However, no differences between BRAF statuses were observed in Stage I-II melanomas (p = .3). In conclusion, BRAF V600E-mutant melanomas show favorable prognostic impact on both disease-free and OSs in all staged melanomas except local disease.

29 July 2015 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
KEKayhan Erturk
Kayhan Erturk
DTDidem Tastekin
Didem Tastekin
MSMurat Serilmez
Murat Serilmez
EDElif Bilgin Doğru
Elif Bilgin Doğru
HBHamza Ugur Bozbey
Hamza Ugur Bozbey
SVSezai Vatansever
Sezai Vatansever

1 February 2016 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
KEKayhan Erturk
Kayhan Erturk
DTDidem Tastekin
Didem Tastekin
EDElif Bilgin Doğru
Elif Bilgin Doğru
MSMurat Serilmez
Murat Serilmez
HBHamza Ugur Bozbey
Hamza Ugur Bozbey
BSBurak Sakar
Burak Sakar

17 February 2024 in Postgraduate Medicine
Verified
Journal Article
Closed access
FTFaruk Tas
Faruk Tas
AOAkın Ozturk
Akın Ozturk
KEKayhan Erturk
Kayhan Erturk
Body mass index (BMI) and serum albumin (ALB) level are long-established markers that reflect the nutritional status and eventually the prognosis of cancer patients. The objective of the study was to determine the clinical significance of these factors and specify their roles in outcomes compared with performance status (PS) and weight loss (WL), which are considered the most significant patient-related prognostic factors in small cell lung cancer (SCLC) treated with platinum-etoposide-based chemotherapy. A total of 378 patients with SCLC were enrolled in the study and analyzed retrospectively. BMI values were similar by clinical stage, whereas the percentages of the patients with WL, low serum ALB, and particularly poor (≥2) PS were significantly higher in patients with extended disease SCLC (ED-SCLC) compared to those with limited disease SCLC (LD-SCLC). In LD-SCLC, patients with poor PS lived for a significantly shorter time than patients with good PS (HR: 7.791, p = 0.0001); however, BMI (HR: 1.035, p = 0.8), WL (HR: 0.857, p = 0.5), and ALB (HR: 0.743, p = 0.3) had no significant effect on the outcome. In ED-SCLC, PS (HR: 4.257, p = 0.0001), WL (HR: 1.677, p = 0.001), and ALB (HR: 0.680, p = 0.007) had an impact on survival, but BMI did not (HR: 0.791, p = 0.08). In LD-SCLC, the univariate analysis showed that only poor PS was correlated with increased mortality (HR: 7.791, p = 0.0001); yet it lost significance in multivariate analysis. In ED-SCLC, poor PS (HR: 4.257, p = 0.0001), WL (HR: 1.667, p = 0.001), and a low ALB level (HR: 0.680, p = 0.007) were shown to be factors for poor prognosis in the univariate analysis; yet only PS remained significant in multivariate analysis (HR: 2.286, p = 0.001). Even though BMI and serum albumin showed no prognostic value in SCLC patients treated with chemotherapy, PS was found to be the most significant prognostic factor in both LD- and ED-SCLC stages.